AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 41 min read$PRGO

Perrigo: Q3 Earnings Snapshot

Perrigo (PRGO) reported a Q3 loss of $27.5M, or 20 cents per share, but adjusted earnings of 60 cents beat estimates. Revenue of $988.6M missed expectations. The company forecasts full-year earnings of $2.25-$2.45 per share.

Original reporting
finance.yahoo.com
Published Nov 4, 2026, 11:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:54 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Perrigo: Q3 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$PRGONeutralMed
01

Why it matters

The earnings release provides fresh data on profitability and revenue trends, influencing short-term price action.

02

Market read

The earnings miss on revenue is likely to weigh on PRGO's stock, while the EPS beat may limit downside.

03

What to watch

Currency effects and one-time gains/losses were adjusted; underlying business trends may be healthier than headline revenue miss suggests.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Perrigo is a global generic and over-the-counter medication manufacturer; the Q3 results were released on Nov 4, 2026.

Company-level read

Ticker impact

$PRGONeutralHigh confidence
Context

Perrigo reported Q3 loss of $27.5M, EPS loss of $0.20 and revenue of $988.6M, missing estimates.

Expected impact

potential downside as market prices in revenue shortfall, with limited upside from EPS beat

Evidence & confidence

First report of the quarterly results; revenue below consensus is a material negative, but EPS beat may offset partially.

Market effects

Sector

Healthcare product manufacturers may see modest pressure from Perrigo's revenue miss.

Regional

U.S. market may see slight dip in consumer health stocks.

Global

Limited, primarily affects U.S. listed healthcare sector.

Counterpoint

What could challenge this read

Investors could view the EPS beat as a sign of cost discipline and consider buying on the dip.

Key entities

  • Company
    Perrigo Co.

    U.S.-listed generic drug manufacturer (ticker PRGO).

Read at source← All news

StoryPerrigo reports Q3 loss, updates outlook and announces Infant Formula divestiture

Also covered by

5 outlets

Related articles

NOV 4
$PRGOMed

Perrigo 2026: Revenue $988.6M, EPS ($0.2) — 10-Q Summary

Perrigo reported 2026 nine-month net sales of $988.6M, down 5.2% YoY, and a net loss of $27.5M, compared to a net income of $7.5M in the prior year. Diluted loss per share was $0.2, versus earnings of $0.05. The decline was attributed to soft consumer demand, lower retailer inventories, and the sale of the Dermacosmetics business. Perrigo plans to sell its Infant Formula business for up to $175M and expects $80M-$100M in annual savings from a two-year efficiency program.

tradingview.com1 min
NOV 4
$PRGOHighAI 8/10

Perrigo Q3 2026 slides show sequential gains amid portfolio shift

Perrigo (NYSE:PRGO) reported Q3 2026 earnings with adjusted EPS of $0.60, beating estimates, while revenue of $989M missed expectations. The stock rose 4.62% to $16.43. Despite year-over-year declines, sequential improvements were noted in sales and margins. The company announced a divestiture of its Infant Formula business for $40M upfront and up to $135M in milestones, part of its strategic transformation.

investing.com2 min
NOV 4
$PRGOHigh

Perrigo Company Slips To Loss In Q3

Perrigo Company reported Q3 net sales of $989M, down from $1.04B last year. It posted a loss of $14.3M, or $0.10 per share, compared to a profit of $12.7M, or $0.09 per share, in the prior year. Adjusted earnings fell to $0.60 per share from $0.80. The company expects fiscal 2026 adjusted earnings of $2.25 to $2.45 per share. Pre-market, PRGO shares were up 1.02% at $15.84.

rttnews.com1 min
NOV 4
$PRGOMedAI 8/10

Perrigo beats earnings but misses on revenue

Perrigo (PRGO) reported Q3 earnings of $0.60 per share, beating estimates by $0.05, but revenue of $989M missed expectations and fell 5.2% YoY. Full-year 2026 EPS guidance was raised to $2.15-$2.35, above consensus. The company plans to sell its Infant Formula business for up to $175M, expecting an impairment loss of $275M-$375M in Q4. Shares rose 0.89% in pre-market trading.

investing.com1 min
NOV 4
$PRGOMed

Perrigo Reports Third Quarter 2026 Financial Results From Continuing Operations

PERRIGO Co plc (PRGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Perrigo Reports Third Quarter 2026 Financial Results From Continuing Operations • Execution of Three-S plan driving sequential improvement in operating results and market share gains across U.S. Store Brand OTC and key European brands • Infant Formula divestiture exp

SEC EDGAR 8-K3 min